Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares Shorted: Short Interest Up 61.6% in October

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totaling 159,295 shares, a growth of 61.6% from the September 30th total of 98,600 shares. Approximately 1.0% of the company’s shares are short sold. Based on an average trading volume of 3,958,965 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ENLV shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Tuesday, September 22nd. Zacks Research lowered Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. Finally, Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4,800.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. WINTON GROUP Ltd purchased a new stake in Enlivex Therapeutics in the 2nd quarter valued at about $55,000. Susquehanna International Group LLP boosted its stake in shares of Enlivex Therapeutics by 1,428.5% in the 2nd quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock worth $87,000 after buying an additional 147,334 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Enlivex Therapeutics by 53.2% in the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after buying an additional 45,303 shares during the last quarter. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

Enlivex Therapeutics Stock Down 17.9%

ENLV stock traded down $0.32 during mid-day trading on Monday, reaching $1.46. 72,260 shares of the company traded hands, compared to its average volume of 23,992. The stock has a market cap of $2.24 million, a price-to-earnings ratio of -0.01 and a beta of 1.63. Enlivex Therapeutics has a fifty-two week low of $1.48 and a fifty-two week high of $434.40. The firm’s 50 day moving average price is $10.56 and its 200 day moving average price is $139.53.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore balance to dysregulated immune responses. The company’s approach is intended to address conditions in which excessive or uncontrolled inflammation contributes to disease progression.

Enlivex’s lead product candidate is Allocetra-OTS, an off-the-shelf cell therapy made from apoptotic cells. The therapy is designed to reprogram the immune system toward a balanced state by helping regulate the activity of immune cells, including macrophages.